PD-1 and CTLA-4 — Drug Target

All drugs that target PD-1 and CTLA-4 — marketed and clinical-stage. Includes 7 drug classes acting on this target.

Drug classes

Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor) · PD-1 inhibitor + CTLA-4 inhibitor combination · Dual checkpoint inhibitor · Bispecific checkpoint inhibitor · Immune checkpoint inhibitor combination · PD-1 inhibitor and CTLA-4 inhibitor combination · Bispecific antibody

Marketed (1)

• Nivolumab in combination with Ipilimumab · Bristol-Myers Squibb · Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor) · Oncology
  Nivolumab and ipilimumab together block two different immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses.

Phase 3 pipeline (5)

• Nivolumab & Ipilimumab · The First Affiliated Hospital of Guangzhou Medical University · PD-1 inhibitor + CTLA-4 inhibitor combination · Oncology
  Nivolumab and ipilimumab together block immune checkpoints (PD-1 and CTLA-4) to unleash T-cell-mediated anti-tumor immunity.
• APVO101 · Medexus Pharma, Inc. · Dual checkpoint inhibitor · Oncology
  APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.
• AK102 · Akeso · Bispecific checkpoint inhibitor · Oncology
  AK102 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.
• Neoadjuvant ipilimumab + nivolumab · The Netherlands Cancer Institute · Immune checkpoint inhibitor combination · Oncology
  This combination blocks two immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses before surgical resection.
• Adjuvant Nivolumab and Ipilimumab · Universitätsklinikum Hamburg-Eppendorf · PD-1 inhibitor and CTLA-4 inhibitor combination · Oncology
  Nivolumab and ipilimumab together block immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor T-cell responses in adjuvant settings.

Phase 2 pipeline (2)

• ABP-745 Dose A · Atom Therapeutics Co., Ltd · Bispecific antibody · Oncology
  ABP-745 is a bispecific antibody that targets and blocks PD-1 and CTLA-4 receptors.
• AK112 high dose · Akeso · Bispecific checkpoint inhibitor · Oncology
  AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.